BRONCHO-VAXOM ADULT 10 CAP

* Broncho-vaxom Adults. Polyvalent immunobiotherapy for the respiratory system.
* Composition:
  7 mg lysat. bacter. lyophilisat. (Haemophilus influenzae, Diplococcus pneumoniae,
  Klebsiella pneuminiae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes
  and viridans, Neisseria catarrhalis).
* Indications:
  Adjuvant therapy in all infections of the respiratory system and of the ears, nose, or throat.
  Prevention of recurrences and of transition of the chronic state.
  BRONCHO-VAXOM is especially recommended as adjuvant therapy in:
  – Acute and chronic bronchitis.
  – Sore throat, tonsillitis, pharyngitis, and laryngitis.
  – Rhinitis sinusitis and otitis.
  – Infections resistant to conventional antibiotics.
  – Bacterial complications of viral infections of the respiratory system. especially in children and the elderly.
* Tolerance:
  Excellent There, are no contraindications. No allergic reactions have been reported.
* Dosage:
  Treatment of acute episode; one capsule daily on an empty stomach until the symptoms disappear.
  but for not, less than 10 days. In cases in which antibiotics are needed. BRONCHO-VAXOM Should be
  given in addition to the antibiotic right from the start of therapy.
  Consolidation therapy one capsule daily on 10 consecutive days per month for three months.
* Protect from heat (15-25 degrees C)
* Produced by: Memphis Co. For Pharm. & Chemical Ind. (MEMCO), Cairo – Egypt. Under licence from: OM Pharma – Switzerland.